Clinical trials: Psychotic Mood Disorders
Bipolar Disorder, Mood Disorders
A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of 3 different doses of paliperidone extended release (ER) compared to placebo in patients diagnosed with Bipolar I Disorder who are experiencing an acute…
- Trial name
- NCT00299715
- Testing
- Paliperidone extended-release
- Volunteers
- 473 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia
The purpose of this study is a noninferiority comparison of the orthostatic tolerability of a dose of 12 mg extended-release (ER) OROS paliperidone with the current recommended initial titration dose (2 mg) of immediate-release…
- Trial name
- NCT00791232
- Testing
- extended-release (ER) OROS paliperidone
- Volunteers
- 113 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic Features
Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy
This Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the efficacy and safety of lurasidone as adjunctive therapy in adult patients with major depressive disorder (MDD) who…
- Trial name
- NCT07781293
- Testing
- Lurasidone, Background Antidepressant Therapy
- Volunteers
- 364 people
- Sponsor
- Bukwang Pharmaceutical
Schizophrenia, Psychotic Disorders
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity.
- Conditions
- Schizophrenia, Psychotic Disorders, Bipolar Disorder
- Trial name
- NCT00044187
- Testing
- Sibutramine
- Where
- 16 sites in United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder, Psychotic Disorders
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00130676
- Testing
- Mifepristone
- Where
- 23 sites in United States
- Volunteers
- 257 people
- Sponsor
- Corcept Therapeutics
Schizophrenia, Bipolar Disorder
A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
The purpose of this study is to evaluate the effects of risperidone compared with other atypical antipsychotic drugs on the physical maturity, growth and development of children, and the risk of prolactin-related adverse events…
- Conditions
- Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
- Trial name
- NCT01050582
- Testing
- Risperidone, Other atypical antipsychotic drugs
- Where
- 28 sites in United States, Belgium and 4 more
- Volunteers
- 244 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder
An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00146523
- Testing
- Mifepristone
- Where
- 19 sites in Bulgaria, Croatia and 2 more
- Volunteers
- 247 people
- Sponsor
- Corcept Therapeutics
Affective Psychosis, Bipolar, Manic Disorder
Phase 3 /Seroquel SR Acute Mania Monotherapy - US
The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Mania for 3 weeks.
- Conditions
- Affective Psychosis, Bipolar, Manic Disorder, Manic-Depressive Psychosis, Mania
- Trial name
- NCT00422123
- Testing
- Quetiapine fumarate (Seroquel) SR
- Where
- 51 sites in United States
- Volunteers
- 447 people
- Sponsor
- AstraZeneca
Bipolar Disorder, Schizophrenia
Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study
Feasibility study of using a digital health feedback system (DHFS) to monitor medication-taking and physiologic and behavioral parameters in patients with bipolar disorder or schizophrenia.
- Trial name
- EMITTER3PSY (NCT01804257)
- Testing
- Digital Health Feedback System
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Proteus Digital Health, Inc.
Major Depressive Disorder, Psychotic Disorders
A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00128479
- Testing
- mifepristone, mifepristone 600 mg, mifepristone 1200 mg
- Where
- 44 sites in United States
- Volunteers
- 443 people
- Sponsor
- Corcept Therapeutics
Schizophrenia, Schizo-Affective Disorder
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.
- Conditions
- Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I
- Trial name
- NCT05025605
- Testing
- BXCL501 80 Micrograms, BXCL501 120 Micrograms, BXCL501 60 Micrograms
- Where
- 5 sites in United States
- Volunteers
- 140 people
- Sponsor
- BioXcel Therapeutics Inc
Major Depressive Disorder, Bi-Polar Disorder
DELPhI Evaluation of Psychiatric Conditions
DELPhI acquisition and analysis software, a QuantalX Neuroscience development, which is designed to measure, analyze, and display brain electrical activity of human electroencephalogram (EEG), to transcranial magnetic stimulation…
- Conditions
- Major Depressive Disorder, Bi-Polar Disorder, ADHD, Schizophrenia
- Trial name
- NCT03842345
- Sponsor
- QuantalX Neuroscience
Schizophrenia
A Study of the Dose Proportionality of Extended Release Paliperidone
The purposes of this study are to evaluate the dose proportionality of 1.5- and 3 mg tablets of paliperidone ER, to document the pharmacokinetics of a 1.5 mg dose of paliperidone ER, and to assess the safety and tolerability of…
- Trial name
- NCT00791167
- Testing
- Paliperidone ER
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Safety and Tolerability of Iloperidone
Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients
Tolerability, undertstanding of the action of the drug in the body, and understanding the effect of the drug in adolescent patients needing treatment with an antipsychotic medication
- Trial name
- NCT01495169
- Testing
- iloperidone (oral tablet)
- Where
- 10 sites in United States
- Volunteers
- 33 people
- Sponsor
- Vanda Pharmaceuticals
Major Depressive Disorder, Psychotic Disorders
An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00128505
- Testing
- Mifepristone
- Where
- 19 sites in Bulgaria, Croatia and 2 more
- Volunteers
- 104 people
- Sponsor
- Corcept Therapeutics
Schizophrenia, Bipolar Disorder
A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in Patients With Schizophrenia or Bipolar I Disorder
The purposes of this study are to evaluate the effects of a potent metabolic enzyme inducer, carbamazepine, on the steady-state pharmacokinetics of orally administered paliperidone ER and to evaluate the safety and tolerability…
- Trial name
- NCT00892125
- Testing
- paliperidone ER; Carbamazepine
- Volunteers
- 64 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Antipsychotic-induced Weight Gain (AIWG)
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with…
- Trial name
- GRATITUDE (NCT03818256)
- Testing
- Miricorilant
- Where
- 27 sites in United States
- Volunteers
- 71 people
- Sponsor
- Corcept Therapeutics
Schizophrenia, Bipolar Disorder
Spanish Validation of Tool Questionnaire to Assess Patients´Perception About Antipsychotic Treatment
Non-interventional, prospective study to validate Spanish version of TOOL questionnaire in patients with schizophrenia and bipolar disorder under antipsychotic treatment
- Trial name
- TOOL (NCT00692133)
- Where
- 32 sites in Spain
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Bipolar Disorder
Topiramate Versus Placebo as add-on Treatment in Patients With Bipolar Disorder in the Outpatient Setting
The purpose of this study is to assess the efficacy and safety of adding topiramate as compared to placebo to the medications a patient with bipolar disorder is already taking (lithium or valproate) to see if adding topiramate…
- Trial name
- NCT00237289
- Testing
- topiramate
- Volunteers
- 287 people
- Sponsor
- Ortho-McNeil Neurologics, Inc.
Schizophrenia, Bipolar Disorder
ADH.E.R.E.: Therapeutic ADHerence and Treatment Strategies: A Mental Health Registry
The purpose of this study is to find out how well new treatment plans are followed by outpatients with major mental illnesses (schizophrenia, bipolar disorder, depression, personality disorder) and to determine the relationship…
- Conditions
- Schizophrenia, Bipolar Disorder, Depression, Personality Disorder
- Trial name
- NCT00264069
- Testing
- antipsychotic, antidepressants
- Volunteers
- 2,622 people
- Sponsor
- Janssen-Cilag, S.A.